Shanghai Bio-heart Biological Technology Co., Ltd.
HKSE 2185.HK
Shanghai Bio-heart Biological Technology Co., Ltd. Shareholders' Equity for the year ending December 31, 2023: USD 105.41 M
-
Shanghai Bio-heart Biological Technology Co., Ltd. Shareholders' Equity for the year ending December 31, 2022 was USD 143.70 M, a -25.04% change year over year.
-
Shanghai Bio-heart Biological Technology Co., Ltd. Shareholders' Equity for the year ending December 31, 2021 was USD 191.69 M, a 50.74% change year over year.
-
Shanghai Bio-heart Biological Technology Co., Ltd. Shareholders' Equity for the year ending December 31, 2020 was USD 127.16 M.
| Date | Shareholders' Equity | Minority Interest | Total Equity | Total Stockholders Equity and Liabilities |
|---|
Don’t Miss A Beat
| CEO | Mr. Li Wang |
| IPO Date | Dec. 23, 2021 |
| Location | China |
| Headquarters | Building 4 |
| Employees | 54 |
| Sector | Healthcare |
| Industries | |
Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. The company focuses on the provision of bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies for the treatment of coronary artery diseases and uncontrolled and resistant hypertension. It is developing Bioheart, a BRS system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and drug coated balloon, a sirolimus drug-eluting balloon catheter designed for instent restenosis. The company has collaboration agreements with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Past 5 years
StockViz Staff
February 2, 2025
Any question? Send us an email